Characterization of on-target adverse events caused by TRK inhibitor therapy.

ABSTRACT:

Background

The tropomyosin receptor kinase (TRK) pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse events (AEs) observed with TRK inhibition, these AEs remain under-recognized, and pain upon drug withdrawal has not previously been reported. As TRK inhibitors are approved by multiple regulatory agencies for TRK or ROS1 fusion-positive cancers, characterizing these AEs and corresponding management strategies is crucial.

Patients and methods

Patients with advanced or unresectable solid tumors treated with a TRK inhibitor were retrospectively identified in a search of clinical databases. Among these patients, the frequency, severity, duration, and management outcomes of AEs including weight gain, dizziness or a

SUBMITTER: Liu D 

PROVIDER: S-EPMC8341080 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature